Eris Lifesciences Limited has informed the Exchange about Investor Presentation

Mgmt Guided Margin ImprovementMgmt Guided Margin PressureCfo Debt Reduction RoadmapInvestor Communications View source PDF

ERIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+2.7%1-day move

₹1352.00

prior close

₹1444.80

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.4+1.4+0.6+0.9+2.7-0.7+0.2+0.7+0.1+2.1+1.0+6.4+8.3—

Up moveDown movePending

AI summary

Eris Lifesciences reported FY26 consolidated revenue of Rs. 3,129 crore (up 8% yoy) and EBITDA of Rs. 1,120 crore (up 10% yoy) with margin expansion from 35% to 36%. The DBF segment grew 11% to Rs. 2,778 crore with EBITDA margin improving to 37%. Key wins include strong insulin market share gains (12% to 16%) and successful Sundae semaglutide launch ranking #1 in injectables by volume. However, the company faced Rs. 105-110 crore revenue loss from delayed/abandoned launches (Saxenda, Aspart, Esaxerenone) and insulin supply constraints. EU-GMP inspection found procedural observations causing delay in CDMO pipeline. PAT surged 73% to Rs. 648 crore including Rs. 150 crore deferred tax benefit. Net debt reduced significantly to 2x EBITDA from 4x in FY24. FY27 guidance targets 1.3x CVM growth for DBF and 18-20% for international business.

Likely market impact

Solid growth with margin expansion, but new product delays and EU regulatory issues may weigh on near-term re-rating. Debt reduction and Sema launch success are positives.